Oct 30th Day 2

09:04

Controlling Infectious Diseases

09:04

Evaluating RSV vaccine candidates: What is missing?

09:04

Promising Immunotherapy Approaches

09:04

Targeted Vaccine Developments

09:04

Vaccine Formulation and Bioprocess

09:04

Vaccine Formulation and Bioprocess

09:04

Vaccine Tech & Delivery

Veterinary
10:05

Characterisation of antibodies to predict protection (systems serology/ immune fingerprinting)

Bioprocess & Manufacture
10:05

Formulation and chromatography methods



Influenza & Respiratory
10:05

RSV animal models: cotton rats, ferrets and cattle

Bioprocess & Manufacture
10:20

Affinity chromatography for vaccines purification



10:35

Morning Networking Break

AMR
11:35

A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates

Immuno-oncology
11:35

Developing personalised T cell therapies to target clonal neoantigens

Bioprocess & Manufacture
11:35

Manufacturing of live vaccines



Influenza & Respiratory
11:35

Models for immune enhanced RSV

Veterinary
12:05

Adjuvant-free vaccine production for both human and animal health

Influenza & Respiratory
12:05

Human challenge models for RSV; benefits and limitations

Immuno-oncology
12:05

Novel combination strategies: IDO1 inhibition with t cell activation approaches

Bioprocess & Manufacture
12:05

Single use and intensified manufacturing processes for next generation vaccines

12:34

Vaccine Development

Immuno-oncology
12:35

Insight on future combination strategies

- Are we effectively incorporating profiling techniques into R&D to better understand the underlying cellular mechanisms and “build” better combinations?
13:04

Profiling & Response

13:35

Networking Lunch & Poster Session

15:04

Vector-borne and parasitic diseases

Immuno-oncology
15:05

Biomarker strategies for patient selection

- Rationale for creating a reference standard for biomarker assays- Clinical implementation of biomarker assays - How do we get these assays up and running in clinical practice?

Bioprocess & Manufacture
15:05

Latest advancements in production process intensification to support demand for affordable vaccines



Clinical Development
15:05

Use of surrogate endpoints, differential efficacy / safety in diverse populations, accurate measures of exposure

16:04

Big Data & Cancer Immunotherapy

16:04

Managing Bacterial Diseases

Immuno-oncology
16:05

The use of genomics to enable rational design of combinatorial immunotherapy

Prof Christian Ottensmeier, Professor, University Of Southampton
Clinical Development
16:50

Challenges in trial design, implementation and safety assessment under clinical development

Bioprocess & Manufacture
17:05

Virus safety for viral vaccines and viral vectors

Veterinary
17:35

Bridging the gap between human and animal health: Bacterial vaccines for managing livestock diseases

Bioprocess & Manufacture
17:35

Delivery platforms catered for the developing countries



Veterinary
17:35

Microbiome and animal health: Dysbiosis in production animals and effects of dietary factors that steer the gut microbiota composition towards a healthy gut ecosystem

AMR
17:35

Typhoid Conjugate Vaccine



17:35

Chair closing remarks of day one followed by Drinks Reception

Bioprocess & Manufacture
17:50

Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing



18:15

Chair closing remarks of day two followed by Drinks Reception host by Neomed Labs

last published: 18/Jul/19 08:45 GMT

Sign Up for Event Updates